Latest News
-
Staggering Return In 1-Yr, LIC stake @ 2.73%: HSBC Has Buy On Electronics Stock, TP Rs 8400 -
1:5 Split: Multibagger LIC-Backed Tata Auto Giant Gears Up For Dividend; Buy Or Accumulate? -
1:10 Stock Split: Record Date In 4 Days On April 19; Buy To Be Eligible? -
Rs 40/Share Dividend: April 23 Fixed As Record Date; Buy The Healthcare Stock To Be Eligible? -
HDFC Mutual Fund Divests 2% Stake in VST Industries for £122 Crore -
Senior Citizens Pay Over £27k Cr in Taxes on FD Interest, Says SBI Report -
Deepika Padukone's Skincare Brand 82°E Announces Offline Launch with Reliance Retail's TIRA -
HCLTech Set for 8% Revenue Increase Through FY24-27, Says Fitch -
Noventiq Set to Expand Indian Workforce by 500, Unveils Bengaluru Office -
RBI Imposes Withdrawal Limit on Sarvodaya Co-op Bank Facing Financial Issues
BNP Paribas Sees 17% Upside In This Multibagger Pharma Stock, Assigns Buy Call
Leading brokerage firm BNP Paribas has given buy rating to the pharmaceuticals sector stock Sun Pharmaceutical Industries Ltd for a target price of Rs 1074 with a potential upside of 17%. The company has a market capitalisation of Rs 2,20,925.34 crore. Check key takeaways below:
Sun Pharmaceutical Industries Ltd Stock Outlook
The current market price of the stock is Rs 920 apiece with a potential upside of 1.53% intraday on Friday. According to BNP Paribas, the stock is showing a potential of upside with a target price of Rs 1074 apiece and potential gain of 17%.
Sun Pharmaceutical Industries Ltd 52-Week High/Low
The stock's 52-week high is quoted at Rs 966 apiece and 52-week low is quoted at Rs 733 apiece, respectively.
Sun Pharmaceutical Industries Ltd Market Capitalisation
The company has a market capitalization of Rs 2,20,925.34 crore.
Sun Pharmaceutical Industries Ltd 5-Years Return
The stock has given multibagger return to investors with 5 years return at 79%, 3 years return at 124% and 1-year return at 20%.
Sun Pharmaceutical Industries Quarterly Results
The company for the quarter ended June 30, 2022 has declared a consolidated total income of Rs 10,763 crore, up 12% from last quarter total income of Rs 9,560 crore. The company has declared a net profit after tax at Rs 2095 crore in the latest quarter.
Sun Pharmaceutical Industries About
Sun Pharmaceutical Industries Ltd has emerged as the fourth largest specialty generic pharmaceutical company in the world. Supported by more than 40 manufacturing facilities, it offers medicinesto more than 100 countries across the globe, according to its official website.
Disclaimer
The stock has been picked from the brokerage report of BNP Paribas. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
